Shots:
- Akeso has reported the P-II (COMPASSION-26) trial results assessing cadonilimab + CT as the 1L treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
- As of Oct 20, 2025 (mFU of >2yrs.), trial showed robust & durable survival benefits, with mPFS of 11.1mos. & mOS of >23mos., showing 12 & 24mos. OS rate of 91.7% & 44.1%, respectively, in pts with locally advanced disease
- The cadonilimab regimen also showed strong tumor control, with an ORR of 33.9% & DCR of 96.4% among evaluable pts (95% % had ≥1 post-baseline tumor assessment). Responses were consistent across locally advanced & metastatic disease
Ref: PRnewswire | Image: Akeso |Press Release
Related News: Akeso Reports P-Ib/II Trial Data on Cadonilimab Combination to Treat NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
